Search clinical trials for: Olaparib durvalumab UV1

Total 1411 results

National University Hospital, Singapore

Unknown

A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas

Ovarian Clear Cell Carcinoma

Singapore
AstraZeneca

Completed

Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (MERMAID-1)

Carcinoma, Non-Small-Cell Lung

United States, Canada, Denmark, France, Netherlands, Belgium, Poland, Taiwan, Thailand, Vietnam, Italy, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Russian Federation, Germany, Hong Kong, Spain, Greece, Switzerland, Australia, Isra... and more
Italian Network for Tumor Biotherapy Foundation
AstraZeneca

Unknown

A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)

Peritoneal Mesothelioma | Pleural Mesothelioma

Italy
National Cancer Institute, Naples

Recruiting

MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer (MITO 35a)

Ovarian Cancer

Italy
AZ-VUB
AstraZeneca; Kom Op Tegen Kanker

Recruiting

Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes (1-2018 BSMO)

Advanced Cancers Harbouring Mutations in HRG

Belgium
AstraZeneca
Merck Sharp & Dohme LLC; GOG Foundation; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Advanced Ovarian Cancer | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response | BRCA Mutation | First Line Platinum Chemotherapy

Korea, Republic of, France, Italy, United States, Israel, Canada, China, Brazil, United Kingdom, Poland, Australia, Japan, Netherlands, Russian Federation, Spain
Hospices Civils de Lyon

Completed

Olaparib in Recurrent IDH-mutant Glioma (OLAGLI)

Recurrent IDH | Mutant High Grade Glioma

France
AstraZeneca
Myriad Genetic Laboratories, Inc.

Withdrawn

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

Platinum Sensitive Relapsed Ovarian Cancer

United States, Korea, Republic of, Peru, United Kingdom, Philippines
Alexander B Olawaiye, MD
AstraZeneca

Recruiting

Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

Ovarian Cancer

United States
Azienda Ospedaliero-Universitaria di Modena

Recruiting

Olaparib in PALB2 Advanced Pancreatic Cancer (PALBOLA)

Metastatic Pancreatic Cancer | Advanced Pancreatic Cancer

Italy
National Cancer Institute (NCI)

Active, not recruiting

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
AstraZeneca

Active, not recruiting

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Metastatic Triple Negative Breast Cancer

United States, Belgium, Italy, Spain, United Kingdom, Canada, Czechia, Poland, France, Korea, Republic of, Germany, Taiwan, Portugal, Netherlands, Ireland
Mayo Clinic

Recruiting

The Use of Ultrasound in Assessing Post-prostatectomy Erectile Dysfunction

Prostate Adenocarcinoma

United States
University of Utah

Enrolling by invitation

Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases

Scleroderma, Systemic | Morphea | Graft Vs Host Disease

United States
Kasr El Aini Hospital

Active, not recruiting

E-cadherin and Integrin Alpha v Beta 1 in Vitiligo

Vitiligo

Egypt
Psoriasis Treatment Center of Central New Jersey

Unknown

An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients

Psoriasis

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca

Completed

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

Metastatic Anaplastic Thyroid Cancer

United States
Sunnybrook Health Sciences Centre
Centre hospitalier de l'Université de Montréal (CHUM); Exactis Innovation; Princess...

Recruiting

Combination of Olaparib and Navitoclax in Women With HGSC and TNBC

Ovarian Cancer | Triple Negative Breast Cancer | High Grade Serous Carcinoma

Canada
Bispebjerg Hospital
The Danish Medical Research Council

Completed

The Vitamin D Dose-Response Relationship

Vitamin D Status

Denmark
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Outcomes of First-line Olaparib Mono-maintenance therapy-a Multicenter, Retrospective Study Using Data From Real-world Clinical Setting

Ovarian Neoplasms
University of Pennsylvania
AstraZeneca; Myriad Genetics, Inc.

Recruiting

Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer (CAPRI)

High Grade Serous Carcinoma

United States
AstraZeneca

Active, not recruiting

Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy (L-MOCA)

Relapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive

China, Malaysia
The Netherlands Cancer Institute

Completed

Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer (REVIVAL)

Breast Cancer | Ovarian Cancer | Advanced Cancer

Netherlands
University of Colorado, Denver

Withdrawn

Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors

Solid Tumor, Adult
MedImmune LLC

Withdrawn

Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC

Microsatellite-stable Colorectal Cancer
ARCAGY/ GINECO GROUP
AstraZeneca

Active, not recruiting

Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer (INeOV)

Ovarian Cancer

France
Cairo University

Unknown

The Effect of NB-UVB on Interleukin-36 Levels in Psoriasis

Psoriasis
Mary Sullivan-Whalen

Completed

Narrowband UVB Treatment in Patients With Vitiligo

Vitiligo

United States
University of Nebraska
AstraZeneca

Recruiting

Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab

Lung Cancer | Carcinoma, Non-Small Cell Lung

United States
Baylor College of Medicine

Completed

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

Mesothelioma

United States
Avita Medical

Completed

Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions

Vitiligo

United States
Avita Medical

Terminated

Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure for Repigmentation of Stable Vitiligo Lesions

Vitiligo

United States
Immunocore Ltd
AstraZeneca

Completed

Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

Malignant Melanoma

United States
Yonsei University
National Cancer Center, Korea; Samsung Medical Center; AstraZeneca; Seoul National... and other collaborators

Unknown

A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D) (KGOG3046)

Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV

Korea, Republic of
Leo Mascarenhas

Completed

Durvalumab in Pediatric and Adolescent Patients

Lymphoma | Solid Tumor | Central Nervous System Tumors

United States
Singapore General Hospital

Completed

Comparison of the Shukla and UN-1 Formulae in the Placement of the Umbilical Venous Catheter Among Neonates

Very Low Birth Weight Infant | Neonatal Hypoglycemia | Extremely Low Birth Weight | Extreme Prematurity,Extremely Low Birthweight

Singapore
Janssen Research & Development, LLC

Completed

A Study Exploring the Use of Challenge Agents in Healthy Volunteers or Participants With a Disease of Interest

Healthy

Belgium
Radboud University Medical Center

Completed

Narrow-Band UVB-Therapy in Psoriasis

Psoriasis

Netherlands
Poveda, Andrés, M.D.
AstraZeneca; PharmaMar

Unknown

Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors

Breast Cancer | Ovarian Cancer | Endometrial Cancer | Advanced Cancer

Spain
The Netherlands Cancer Institute

Completed

Olaparib and Radiotherapy in Inoperable Breast Cancer

Locally Advanced Malignant Neoplasm | Triple-Negative Invasive Breast Carcinoma | Inflammatory Breast Carcinoma

Netherlands
National Cancer Institute (NCI)

Active, not recruiting

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States
Tae Won Kim

Terminated

The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors

Colorectal Cancer | Solid Tumor

Korea, Republic of
Celgene

Completed

A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION-MM-005)

Multiple Myeloma

United States, Spain, Austria, Greece, Netherlands, Sweden
Yale University

Completed

TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer

Colorectal Cancer

United States
UNICANCER
ARCAGY/ GINECO GROUP; SOLTI Breast Cancer Research Group

Active, not recruiting

Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. (DOLAF)

ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer | a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status

France
University of Texas Southwestern Medical Center

Completed

Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea

Scleroderma, Localized | Morphea | Scleroderma, Circumscribed

United States
Brigham and Women's Hospital
Dana-Farber Cancer Institute

Terminated

UVB Phototherapy Treatment of Oral Chronic GVHD

Oral Chronic Graft-Versus-Host Disease

United States
University of Utah
Repare Therapeutics

Recruiting

RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia (CORONADO CLL)

Chronic Lymphocytic Leukemia

United States
Gruppo Oncologico del Nord-Ovest

Recruiting

Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer (POINT)

Nasopharyngeal Carcinoma

Italy
AstraZeneca

Completed

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

Ovarian Cancer

Canada, Czechia, Poland, Romania, United States, Belgium, France, Russian Federation, United Kingdom, Israel, Spain, Germany, Austria, Netherlands, Australia, Estonia, Ukraine

Search clinical trials for: Olaparib durvalumab UV1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations